Dow Jones
32.244,58 +382,60 (+1,20%) Nasdaq
11.675,54 +45,02 (+0,39%) Nikkei 225
26.945,67 -388,12 (-1,42%) EUR/USD
1,0716 -0,0010 (-0,10%) Bitcoin EUR
26.038,83 +401,42 (+1,57%) CMC Crypto 200
604,99 +5,33 (+0,89%)
Terns Pharmaceuticals, Inc. (TERN)
Dopo ore:
| Chiusura precedente | 10,09 |
| Aperto | 10,15 |
| Denaro | 9,87 x 1200 |
| Lettera | 10,66 x 1200 |
| Min-Max giorno | 9,72 - 10,42 |
| Intervallo di 52 settimane | 1,45 - 11,44 |
| Volume | |
| Media Volume | 299.571 |
| Capitalizzazione | 489,221M |
| Beta (5 anni mensile) | -1,05 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,26 |
| Prossima data utili | 24 mar 2023 - 08 apr 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,60 |
- GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at a major upcoming oncology conference IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; on track to initiate first-in-human clinical t
- GlobeNewswire
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023 at 10:10 a.m.
- GlobeNewswire
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference
FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET
